[A20-42] Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 03.08.2020
Commission awarded on 29.04.2020 by the Federal Joint Committee (G-BA).
Adult patients with ALK-positive advanced NSCLC who have not been previously treated with an ALK inhibitor
Patients with brain metastases at the start of treatment: indication of minor added benefit; patients without brain metastases at the start of treatment: hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A19-08||Brigatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-85||Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42||Commission completed|
|G20-21||Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42||Commission completed|